Introduction: In over of 99% cases of cervical cancer its appearing is preceded by persistent cervical epithelium infection caused by high-risk oncogenic types of human papillomavirus (HPV). The aim of the study was to examine the distribution of high-risk oncogenic HPV types compared to patohistological diagnoses of cervical diseases in women. Materials and methods: The study included 56 women with suspected premalignant and malignant cervical lesions, due to suspected colposcopic and cytological findings (Papanicolaou test). The HPV typing by "in situ" hybridization method on high-risk HPV types 16, 18, 31 and 33 was performed in all patients from cervical smear as well as cervical biopsy. Histological findings of cervical biopsy was a "gold standard" in the analysis of materials. Results: Histologically detected premalignant or malignant changes of the cervix were found at 34 (60.7%) of all 56 examined women: 17 of them had LSIL, 13 of them had HSIL, while 4 had squamous cell carcinoma. A positive HPV test had a 47 (84%) of them with a prove of the presence of one or more types of HPV. The most common type of virus was HPV 16 and it was detected in 27 (48.2%) women, followed by HPV 31 that was detected in 26 (46.4%) women, HPV 18 in 18 (32.1%) of women and HPV 33 in 4 (7.1%) women. The infection caused by oncogenic type HPV16 was significantly more frequent in patients with HSIL and cervical cancer (p<0,001), while the infection caused by oncogenic type HPV 31 was significantly more frequent in patients with LSIL and cervicitis (p=0,003). The distribution of HPV 18 and HPV 33 types was not statistically significantly different in patients with different histological findings (HPV 18, p = 0.41; HPV 33, p = 1.0). Conclusion: Based on our results we can conclude that there is a good correlation of HPV infection with pre-malignant cervical lesions and cervical cancer. The incidence of HPV type 16 infection increased with severity of cervical lesions and it is usually detected high-risk oncogenic type virus in women with severe cervical lesions type like HSIL and cancer are. HPV 31 is the most common high-risk type of HPV of mild type lesions, like LSIL and cervicitis are. We believe that women infected by high-risk oncogenic HPV types, although without histologically diagnose of cervical lesion, should be more frequent controle by colposcopy and cytology (Papanicolaou) test, because of possible disease progression to a more advanced level.
Munoz N, Bosch F, Desanjose S, Tafur L, Izarzugaza I, Gili M. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer. 1992;743–9.
2.
Schiffman M, Bauer H, Hoover R, Glass A, Cadell D, Rush B. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993;958.
3.
Hildesheim A, Schiffman M, Gravitt P, Glass A, Greer C, Zhang T. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;235–40.
4.
Iarc. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon International Agency for Research on Cancer. 1995;
5.
Franco E, Villa L, Sobrinho J, Prado J, Rousseau M, Desy M. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;1415–23.
6.
Zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nature. 2002;342–50.
7.
Heley S. Human papillomavirus: beware the infection you can´t see. ust Fam Physician. 2003;311–5.
8.
Villiers D, Fauquet EM, Brocer C, Bernard T, Zur Hausen HU, H. Classification of papillomaviruses. Virology. 2004;17–27.
9.
Subramanya D, Grivas P. HPV and cervical cancer: updates on an established relationship. Postgrad Med. 2008;7–13.
10.
Vitković L, Mitić B, Piperski V, Trajković G, Anđeliković Z, Vukićević D, et al. Ekspresija proteina p16INK4a u normalnom i displastično promenjenom epitelu grlića materice. Naučni časopis Medicinskog fakulteta i Društva lekara Kosova i Metohije SLD-Praxis medica. 2011;(3–4):13–7.
11.
Gharizadeh B, Calantari M, Garsia C, Johanson B, Nyren P. Typing of human papillomavirus by pyrosequencing. Lab Invest. 2001;673–9.
12.
Von K, Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. European Journal of Cancer. 2002;2229–42.
13.
Iarc. IARC Handbooks of Cancer Research Prevention. Cervix Cancer Screening. 2005;
14.
Stanimirоvić B, Atanacković J, Babić M, Berisavac M, Bošković V, Vujkov T, et al. 2006;
15.
Iarc. IARC Monographs on the evaluation of Carcinogenic Risks to Humans. 2007;
16.
Evander M, Frazer I, Payne E, Qi Y, Hengst K, Mcmillan N. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol. 1997;2449–56.
17.
Letian T, Tianyu Z. Cellular receptor binding and entry of human papillomavirus. J Virol. 2010;(2).
18.
Spoden G, Kühling L, Cordes N, Frenzel B, Sapp M, Boller K, et al. Human Papillomavirus Types 16, 18 and 31 Share Similar Endocytic Requirements for Entry. J Virol. 2013;(13):7765–73.
19.
Vitković L. Značaj molekularnih markera u histološkoj i citološkoj analizi epitela grlića materice. 2011;
20.
Day P, Thompson C, Buck C, Pang Y, Lowy D, Schiller J. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol. 2007;8784–92.
21.
Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P. Type-Dependent Integration Frequency of Human Papillomavirus Genomes in Cervical Lesions. Cancer Res. 2008;(1):307–13.
22.
Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;3–8.
23.
Parkin D, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;(3):11–25.
24.
Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci. 2006;525–41.
25.
Vitković L. Histološko-citološka korelacija nalaza i pouzdanost Papanicolau testa u otkrivanju premalignih i malignih promena na grliću materice. Naučni časopis Medicinskog fakulteta i Društva lekara Kosova i Metohije SLD-Praxis medica. STRUČNI. 2015;(1):39–44.
26.
Zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;690–8.
27.
Kalof A, Cooper K. P16INK4a Imunoexpression: Surrogate Marker of High-risk HPV and High-grade Cervical Intraepithelial Neoplasia. Adv Anat Pathol. 2006;190–4.
28.
Mulvany N, Allen D, Wilson S. Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. Pathology. 2008;(4):335–44.
29.
Šimunić V I Sar. 2001;
30.
Murphy N, Ring M, Killaea A, Uhlmann V, ’donovan O, Mulcahy M, et al. p16INK4A as a marker for cervical dyskariosis: CIN and cGIN in cervical biopsies and Thin PrepTM smears. J Clin Pathol. 2003;53–63.
Lacey C. Assessment of exposure to sexually transmitted agents other than human papillomavirus. IARC Scientific Publications. 1992;(119):93–105.
34.
Halfon P, Trepo E, Antoniotti G, Bernot C, Cart-Lamy P, Khiri H. Prospective Evaluation of the Hybrid Capture 2 and AMPLICOR Human Papillomavirus (HPV) Test for detection of 13 High-Risk HPV Genotypes in Atypical Aquamous cells of Uncertain Significance. J Clin Microbiol. 2007;(2):313–6.
35.
Reddout N, Christensen T, Bunell A, Jensen D, Jonson D, O´malley S. High risk HPV types 18 and 16 are potent modulators of oral squamous cell carcinoma phenotypes in vitro. Infect Agent Cancer. 2007;21–33.
36.
Uuskũla A, Kals M, Kosenkanius L, Mcnutt L, Hovitz D, J. Population based type-specific, prevalence of high-risk human papillomavirus infection in Estonia. Infectius Diseases. 2010;63.
37.
Lalević-Vasić B, Lj M. 2006;342–3.
38.
Krstić Lj. Papillomaviridae. U Specijalna virusologija, Savremena Administricija. 19AD;129–31.
39.
Pater M, Pater. Human papillomavirus types 16 and 18 sequences in carcinoma cell lines of the cervix. Virology. 1985;313–8.
40.
Villers D, Schneider E, Gross A, Zur Hausen G, H. Analysis of benign and malignant urogenital tumors for human papilloma virus infection by labeling cellular DNA. Med Microb Immunol. 1986;281–4.
41.
Villiers D, Fauquet EM, Brocer C, Bernard T, Zur Hausen HU, H. Classification of papillomaviruses. Virology. 2004;17–27.
42.
Milutin -Gasperov N, Sabol I, Halec G, Matovina M, Grce M. Retrospective study of prevalence of high risk human papillomaviruses among croatian women. Coll Antropol. 2007;(Suppl 2):89–96.
43.
Lowy D, Schiller J. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;1167–73.
44.
Stojanović J, Magić Z, Milačić M, Nenadić D, Stanimirović B, Vukičević D. Distribution of high-risk HPV tyres in Yugoslav women with cervical neoplasia. J Buon. 2002;251–6.
45.
Lorincz A, Reid R, Jensen A, Greenberg M, Lancaster W, Kurman R. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types. Ostret Gynecol. 1992;328.
46.
Munoz N, Bosch F, De Sanjose S, Herrero R, Castellsague X, Shah K. Epidemiologic clasiffication of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;518–27.
47.
Clifford G, Smith J, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;63–73.
48.
Murphy N, Ring M, Killaea A, Uhlmann V, ’donovan O, Mulcahy M, et al. p16INK4A as a marker for cervical dyskariosis: CIN and cGIN in cervical biopsies and Thin PrepTM smears. J Clin Pathol. 2003;53–63.
49.
Vitković L, Piperski V, Mitić N, Anđelković Z, Savić S, Leštarević S, et al. Značaj ekspresije proteina p16ink4a u histološkoj analizi epitela grlića materice. III Kongres Srpskog anatomskog društva Srbije sa međunarodnim učešćem. Zbornik sažetaka Medicinski fakultet u Nišu. 6AD;171–2.
50.
Vitković L, Perišić Ž, Mitić N, Piperski V, Trajković G. Importance of P16INK4a in cervical cytology. 36th European Congress of Cytology Istambul. Cytopathology. 2011;
51.
Ho G, Palan P, Basu J, Romney S, Kadish A, Mikhail M. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer. 1998;594–9.
52.
Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;3–8.
53.
Moscicki A. Impact of HPV infection in adolescent populations. J Adoles Health. 2005;3–9.
54.
Benton E, Arends, Mj. Human papillomavirus in the immunosuppressed. 1996;271–9.
55.
Ostor A. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;(2):186–92.
56.
Tindle R. Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol. 1996;(5):643–50.
57.
Queiroz C, Silva T, Alves V, Villa L, Costa M, Travassos A. P16INK4a expression as a potential prognostic marker in cervical pre-neoplastic and neoplastic lesions. Pathol Res Pract. 2006;(2):77–83.
58.
Clavel C, Masure M, Bory J. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001;(12):1616–23.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
